Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00838084 | A Safety Study of LY2811376 Single Doses in Healthy Subjects | PHASE1 | COMPLETED | 61 | — | — | Dec 1, 2008 | Jun 1, 2009 | Jul 15, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| LY2811376 Part 1 | EXPERIMENTAL | LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods. |
| Placebo Part 1 | PLACEBO_COMPARATOR | once a day or twice a day for 1 day in up to 3 periods. |
| LY2811376 - Part 2 low dose | EXPERIMENTAL | Single dose of LY2811376, dose determined by part 1 |
| LY2811376 - Part 2 high dose | EXPERIMENTAL | Single dose of LY2811376, dose determined by part 1 |
| Placebo Part 2 | PLACEBO_COMPARATOR | single dose |
| Name | Type | Description |
|---|---|---|
| LY2811376 | DRUG | Oral capsules |
| Placebo | DRUG | Oral capsules |
Inclusion Criteria: * Healthy men and nonchild-bearing potential women * 20 years or older * Body mass index between 18-32kg/m2 Exclusion Criteria: * Taking over-the-counter or prescription medication with the exception of vitamins or minerals or stable doses of thyroid or estrogen hormone replac...